Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study-Reference-Cited by-同舟云学术

Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study

Published:2024-05 Issue:5 Volume:24 Page:546-556
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bertran Marta,D'Aeth Joshua C,Abdullahi Fariyo,Eletu Seyi,Andrews Nick J,Ramsay Mary E,Litt David J,Ladhani Shamez N

Funder

UK Health Security Agency - Colindale

Publisher

Elsevier BV

Reference31 articles.

1. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study;Andrews;Lancet Infect Dis,2014

2. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects;Davis;Vaccine,2013

3. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers;Goldblatt;Pediatr Infect Dis J,2006

4. Effect of the 13-valent pneumococcal conjugate vaccine on IPD in England and Wales 4 years after its introduction: an observational cohort study;Waight;Lancet Infect Dis,2015

5. Rapid increase in non-vaccine serotypes causing IPD in England and Wales, 2000–17: a prospective national observational cohort study;Ladhani;Lancet Infect Dis,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supporting vaccine (co)-administration decisions: Development and validation of a tool for assessing the risk of severe outcomes due to lower respiratory tract infections;Respiratory Medicine;2024-10

2. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study;The Lancet Public Health;2024-09

3. New-generation pneumococcal vaccines for children;The Lancet Public Health;2024-09

4. CC180 clade dynamics does not universally explainStreptococcus pneumoniaeserotype 3 persistence post-vaccine: a global comparative population genomics study;2024-08-30

5. Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study;Clinical Infectious Diseases;2024-08-14